Preview

Epilepsia and paroxyzmal conditions

Advanced search

MODERN TECHNOLOGIES IN THERAPEUTIC DRUG MONITORING (REVIEW)

Full Text:

Abstract

Abstract: due to the emergence of new technologies in a pharmakokinetics, a pharmacogenetics and analytical chemistry, the medicine comes to qualitatively new stage of development. Therapeutic drug monitoring as the mean of the real time pharmacotherapy efficiency control becomes the basis of rational therapy in modern medicine. In the article various aspects of the therapeutic drug monitoring (TDM) as subsection of clinical pharmacology are discussed. The main indications to carrying out TDM and the main TDM procedures are submitted. Value of TDM for an epileptology is discussed. The special attention is paid to the bioanalytical methods and new methodical approaches (such as non-invasive drug monitoring and equilibrium dialysis) applied in TDM. TDM role as an independent discipline of a medical sciences, with concentration on modern pharmacokinetics computer programs is separately analyzed.

About the Authors

D. A. Abaimov
Scientific Center of Neurology RAS, Moscow
Russian Federation


A. K. Sariev
Scientific Center of Neurology RAS, Moscow
Russian Federation


T. Yu. Noskova
Scientific Center of Neurology RAS, Moscow
Russian Federation


V. V. Shvedkov
Scientific Center of Neurology RAS, Moscow
Russian Federation


M. V. Shiryaeva
Scientific Center of Neurology RAS, Moscow
Russian Federation


E. Yu. Styrova
Scientific Center of Neurology RAS, Moscow
Russian Federation


D. I. Prokhorov
Scientific Center of Neurology RAS, Moscow
Russian Federation


R. D. Seyfulla
Scientific Center of Neurology RAS, Moscow
Russian Federation


References

1. Белоусов Ю.Б., Гуревич К.Г. Клиническая фармакокинетика. Практика дозирования веществ. М. 2005.

2. Мирошниченко И.И. Рациональное дозирование и мониторинг лекарственных средств. М. 2011.

3. Носкова Т.Ю. Возможности оптимизации фармакотерапии эпилепсии. Анналы клинической и экспериментальной неврологии. 2009; 3: 37-40.

4. Родионов А.А., Кабанова И.А., Сейфулла Р.Д., Тимофеев А.Б. Терапевтический лекарственный мониторинг при эпилепсии: альтернативные подходы. Анналы клинической и экспериментальной неврологии. 2008; 2: 14-19.

5. Сариев А.К., Носкова Т.Ю., Абаимов Д.А., Суслина З.А. Новые методы в оптимизации фармакотерапии эпилепсии: опыт внедрения байесовского фармакокинетического моделирования. Эпилепсия и пароксизмальные состояния. 2012; 4: 40-47.

6. Сергиенко В.И., Бондарева И.Б. Математическая статистика в клинических исследованиях 2-е изд., перераб. и доп. М. 2006.

7. Соколов А.В. Терапевтический лекарственный мониторинг. Качественная клиническая практика. 2002: 78-88.

8. Adaway J.E., Keevil B.G. Therapeutic drug monitoring and LC-MS/MS. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2012; 883-884: 33-49.

9. Bondareva I.B., Sokolov A.V., Tischenkova I.F. et al. Population pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage. J Clin. Pharm. Ther. 2001; 26: 213-223.

10. Brandt C., Baumann P., Eckermann G. et al. Therapeutic drug monitoring in epileptology and psychiatry. Nervenarzt. 2008; 79: 167-174.

11. Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin. Chim. Acta. 2007; 377: 1-13.

12. Gervasini G., Benitez J., Carrillo J.A. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur. J. Clin. Pharmacol. 66: 755-774.

13. Hallworth M. WI. Therapeutic drug monitoring and laboratory medicine. London: ACB Venture Publications, 2008.

14. Hiemke C. Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Eur. Arch. Psychiatry. Clin. Neurosci. 2008; 258 Suppl 1: 21-27.

15. Jelliffe R.W., Schumitzky A., Bayard D. et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new ‘multiple model’ dosage design, bayesian feedback and individualised target goals. Clin Pharmacokinet. 1998; 34: 57-77.

16. Johanssen S.I., Landmark C.J. Antiepileptic drug interactions – principles and clinical implications. Curr. Neuropharmacol. 2010; 8: 254-267.

17. Jones M.D., Ryan M., Miles M.V. et al. Stability of salivary concentrations of the newer antiepileptic drugs in the postal system. Ther. Drug. Monit. 2005; 27: 576-579.


For citation:


Abaimov D.A., Sariev A.K., Noskova T.Y., Shvedkov V.V., Shiryaeva M.V., Styrova E.Y., Prokhorov D.I., Seyfulla R.D. MODERN TECHNOLOGIES IN THERAPEUTIC DRUG MONITORING (REVIEW). Epilepsia and paroxyzmal conditions. 2013;5(2):31-41. (In Russ.)

Views: 100


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)